Jazz Pharmaceuticals’ Xywav shows efficacy in narcolepsy, idiopathic hypersomnia

Jazz Pharmaceuticals (JAZZ) announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych Congress in Boston October 29 through November 2. The data includes the top-line results of the Phase 4 DUET trial, evaluating the effectiveness of low-sodium oxybate on key sleep outcomes in adults with narcolepsy or idiopathic hypersomnia, or IH. Notably, these DUET data are the first to show prospective improvements on excessive daytime sleepiness, or EDS, as well as key polysomnography – PSG – outcomes of sleep disruption, among adults with narcolepsy treated with Xywav oral solution. Further, new DUET data evaluating nighttime Xywav treatment in adults with IH demonstrate clinical improvements on daytime symptoms, including sleep inertia measured by the Patient Global Impression of Change. Observed adverse events were consistent with the known safety profile of Xywav, with the most common including nausea, dizziness and headache.